Phase 2 N=107 Phase 2 Nab® -Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC)
Pancreatic Neoplasms
Primary: Kaplan-Meier Estimates for Time to Treatment Failure (TTF) — 9.0 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=28 FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial
Locally Advanced Pancreatic Cancer · Pancreatic Cancer
Primary: Response Rate of FOLFOX-A for Patients With Locally Advanced Pancreatic Cancer. — 0; 12; 12; 4 Participants
Phase 2 N=40 Capecitabine and Oxaliplatin in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma
Pancreatic Cancer
Primary: Response Rate — .125 proportion of participants
Phase 2 N=51 Panitumumab, Chemotherapy, and External-Beam Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot be Removed by Surgery
Pancreatic Cancer
Primary: One Year Survival Rate — 0.502 proportion of patients
Phase 2 N=11 Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer
Pancreatic Adenocarcinoma · Resectable Pancreatic Carcinoma · Stage I Pancreatic Cancer
Primary: Number of Participants With Progressive Disease, — 2 Participants
Phase 2 N=202 Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer
Pancreatic Cancer
Primary: Overall Survival — 375; 393 Days — p=0.3864
Phase 3 N=80 A Study of Erlotinib in Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer
Pancreatic Cancer
Primary: Percentage of Participants With Adverse Events (AEs) — 78.8 percentage of participants
Phase 2 N=8 AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer
Pancreatic Neoplasms
Primary: Overall Survival (OS) — 210; 171 Days — p=0.1026
Phase 3 N=861 Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas
Metastatic Pancreatic Cancer
Primary: Overall Survival (OS) — 8.5; 6.7 months — p=<0.0001
Phase 1 N=27 Study of Low-Dose Fractionated Radiotherapy in Patients With Locally Advanced Metastatic Pancreatic Cancer
Pancreatic Carcinoma Non-resectable · Metastatic Pancreatic Cancer
Primary: To Determine the Dose Limiting Toxicities — 27 participants
Phase 2 N=20 Abraxane Therapy in Patients With Pancreatic Cancer Who Failed First-Line Gemcitabine Therapy
Pancreatic Cancer
Primary: Overall Survival Rate at 6 Months — 58 percentage of participants
Phase 2 N=61 Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer
Pancreatic Cancer
Primary: Overall Response Rate (ORR) — 6.9 percentage of participants
Phase 2 N=29 Combination Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer
Pancreatic Cancer
Primary: Surgical Exploration — 4; 6; 9 Participants
Phase 2 N=54 Trial of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma
Locally Advanced Pancreatic Adenocarcinoma
Primary: Number of Subjects With Treatment Emergent Adverse Events (Safety and Tolerability) — 3; 3; 4; 23 Participants
Phase 2 N=11 A Trial of Chemo & Radiation Therapy for Pancreatic Cancer
Pancreatic Cancer
Primary: Progression-free Survival of Patients With Locally Advanced Pancreatic Cancer Treated With Concurrent Gemcitabine, 5-FU, Cetuximab and External Beam Radiation Therapy…
Phase 2 N=44 Gemcitabine and Imatinib Mesylate as First-Line Therapy in Patients With Locally Adv. or Metastatic Pancreatic Cancer
Pancreatic Cancer
Primary: Progression-free Survival — 3.9 months
Phase 2 N=46 Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Adenocarcinoma of the Pancreas · Recurrent Pancreatic Cancer · Stage III Pancreatic Cancer
Primary: Overall Survival (OS) — 7.3 months
Phase 2 N=50 BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial
Metastatic Pancreatic Cancer
Primary: Survival for Patients With Metastatic Pancreatic Cancer With First-line Treatment With FOLFOX-A as Compared to Historical Controls of Gemcitabine Alone. — 5; 11 months
Phase 2 N=15 Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients
Adenocarcinoma of the Pancreas · Pancreatic Cancer · Recurrent Pancreatic Cancer
Primary: Objective Response (Complete and Partial) Evaluated Using RECIST Criteria — 0 participants
Phase 2 N=170 A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Neoplasms · Neoplasm Metastasis · Pancreatic Cancer
Primary: Phase 1b: Recommended Phase 2 Dose — 300 milligrams (mg)
Phase 3 N=693 Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
Primary: Overall Survival — 8.9; 7.6 months
Phase 2 N=127 FIrst Line Treatment of Metastatic Pancreatic Cancer: Sequential Nab-paclitaxel + Gemcitabine/FOLFIRI.3 VS Nab-paclitaxel + Gemcitabine
Metastatic Pancreatic Cancer
Primary: Percentage of Patients Alive and Without Radiological and/or Clinical Progression 6 Months After the Randomization — 28; 14 Participants
Phase 3 N=27 Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer
Pancreatic Cancer
Primary: Progression-free Survival (PFS) — 6.5; 8.4 months
Phase 1 N=4 Regional Chemotherapy in Locally Advanced Pancreatic Cancer: RECLAP Trial
Histologically or Cytologically Confirmed Pancreatic Ca · Unresectable or Borderline Resectable Pancreatic Ca
Primary: Number of Participants With Dose Limiting Toxicity (DLT ) — 0; 1; 0; 0 Participants
Phase 3 N=284 Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer
Pancreatic Cancer Non-resectable
Primary: Overall Survival — 17.25; 17.94 months — p=0.5487
Phase 2 N=25 Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA
Stage IV Pancreatic Cancer
Primary: Complete Response Rate — 2; 15; 4; 3 Participants
Phase 1 N=30 Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer
Pancreatic Cancer
Primary: Percent of Patients Experiencing an Unacceptable Toxicity — 6.67; 6.67 Percentage of Participants
Phase 2 N=28 Phase 2 Study of S-1 in Advanced or Metastatic Pancreatic Cancer
Locally Advanced or Metastatic Pancreatic Cancer
Primary: Overall Tumor Response Rate (ORR) — 4.0; 9.5 percentage of participants
Phase 2 N=273 First-line Metastatic Pancreatic Cancer : FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem
Metastatic Pancreatic Cancer
Primary: Percentage of Patients Alive and Without Radiological and/or Clinical Progression 6 Months After the Randomization. — 41; 39; 30 Participants
Phase 2 N=67 Gemcitabine Plus Albumin-bound Paclitaxel In Patients With Advanced Metastatic Pancreatic Cancer
Metastatic Pancreatic Cancer
Primary: Number of Participants With Dose-limiting Toxicities — 4; 0; 1 participants